KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Beginning Cash Balance: 2009-2025

Historic Beginning Cash Balance for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $300.5 million.

  • Pacira BioSciences' Beginning Cash Balance rose 21.63% to $300.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.0 million, marking a year-over-year increase of 148.15%. This contributed to the annual value of $153.3 million for FY2024, which is 47.21% up from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Beginning Cash Balance is $300.5 million, which was up 5.95% from $283.6 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Beginning Cash Balance peaked at $585.6 million during Q1 2022, and registered a low of $35.5 million during Q2 2023.
  • In the last 3 years, Pacira BioSciences' Beginning Cash Balance had a median value of $184.1 million in 2024 and averaged $183.3 million.
  • Its Beginning Cash Balance has fluctuated over the past 5 years, first skyrocketed by 485.83% in 2022, then slumped by 84.32% in 2023.
  • Quarterly analysis of 5 years shows Pacira BioSciences' Beginning Cash Balance stood at $134.0 million in 2021, then decreased by 18.36% to $109.4 million in 2022, then decreased by 9.42% to $99.1 million in 2023, then surged by 148.15% to $246.0 million in 2024, then increased by 21.63% to $300.5 million in 2025.
  • Its Beginning Cash Balance stands at $300.5 million for Q3 2025, versus $283.6 million for Q2 2025 and $276.8 million for Q1 2025.